Clinical Trial Update: Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study comparing oral ibrexafungin (SCY-078) to fluconazole for acute vulvovaginal candidiasis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Fluconazole (Fluconazole)
• ibrexafungin (ibrexafungep)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Candida Vulvovaginitis | Phase 2 | Status: COMPLETED | Results posted: 2021-08-12